The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Natalizumab for Active Crohn's Disease
Abstract
BACKGROUND: In chronic inflammatory conditions such as Crohn's disease, the migration of leukocytes from the circulation into the parenchyma and their activation within inflammatory sites are mediated in part by alpha4 integrins. METHODS: We conducted a double-blind, placebo-controlled trial of the alpha4 integrin-specific humanized monoclonal antibody natalizumab in 248 patients with moderate-to-severe Crohn's disease. Patients were randomly assigned to receive one of four treatments: two infusions of placebo; one infusion of 3 mg of natalizumab per kilogram of body weight, followed by placebo; two infusions of 3 mg of natalizumab per kilogram; or two infusions of 6 mg of natalizumab per kilogram. Infusions were given four weeks apart. Outcomes included changes in scores for the Crohn's Disease Activity Index (higher scores indicate more severe disease), the health-related quality of life, and C-reactive protein levels. RESULTS: The group given two infusions of 6 mg of natalizumab per kilogram did not have a significantly higher rate of clinical remission (defined by a score of less than 150 on the Crohn's Disease Activity Index) than the placebo group at week 6 (the prospectively defined primary end point in the efficacy analysis). However, both groups that received two infusions of natalizumab had higher remission rates than the placebo group at multiple time points. Natalizumab also produced a significant improvement in response rates (defined by a reduction of at least 70 points in the score on the Crohn's Disease Activity Index). The highest remission rate was 44 percent and the highest response rate was 71 percent (at week 6 in the group given two infusions of 3 mg per kilogram). Overall, the two infusions of 6 mg of natalizumab per kilogram and of 3 mg per kilogram had similar effects. The quality of life improved in all natalizumab groups; C-reactive protein levels improved in groups receiving two infusions of natalizumab. The rates of adverse events were similar in all four groups. CONCLUSIONS: Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Unbalanced Repeated-Measures Models with Structured Covariance Matrices
Jennrich, R. I., & Schluchter, M. D. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,325
Endothelial-Leukocyte Adhesion Molecules
Bevilacqua, M. P. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.004003 · Cited by 1,293
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Irvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D., Saibil, F., & McDonald, J. W. D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 712
Landis, J. R., Heyman, E. R., & Koch, G. G. (1978) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402373 · Cited by 454
The pathophysiologic role of alpha 4 integrins in vivo.
Lobb, R. R., & Hemler, M. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117519 · Cited by 378
Hesterberg, P., Winsor-Hines, D., Briskin, M., Soler-Ferran, D., Merrill, C., Mackay, C., Newman, W., & Ringler, D. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898653 · Cited by 323
Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.
Podolsky, D. K., Lobb, R., King, N., Benjamin, C. D., Pepinsky, B., Sehgal, P., & deBeaumont, M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116575 · Cited by 320
Gordon, F. H., Lai, C. W. Y., Hamilton, M. I., Allison, M. C., Srivastava, E. D., Fouweather, M. G., Donoghue, S., Greenlees, C., Subhani, J., Amlot, P. L., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.26260 · Cited by 314
Self-citationKoopman, G., Keehnen, R. M. J., Lindhout, E., Newman, W., Shimizu, Y., van Seventer, G. A., de Groot, C., & Pals, S. T. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.8.3760 · Cited by 303
Issekutz, T. B. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.12.4178 · Cited by 204
Gordon, F. H., Hamilton, M. I., Donoghue, S., Greenlees, C., Palmer, T., Rowley‐Jones, D., Dhillon, A. P., Amlot, P. L., & Pounder, R. E. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01205.x · Cited by 164
Self-citationFarstad, I. N., Halstensen, T. S., Kvale, D., FAUSA, O., & Brandtzaeg, P. (1997) · PubMed Central · Cited by 97
Damle, N. K., Klussman, K., Leytze, G., Aruffo, A. A., Linsley, P. S., & Ledbetter, J. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2368 · Cited by 96
The α4β1/VCAM-1 adhesion pathway in physiology and disease
Postigo, A. A., Teixidó, J., & Sánchez‐Madrid, F. (1993) · Research in Immunology · doi:10.1016/s0923-2494(93)80057-6 · Cited by 79
Johnston, B., WALTER, U. M., Issekutz, A. C., Issekutz, T. B., Anderson, D. C., & Kubes, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.9.4514 · Cited by 72
Leussink, V. I., Zettl, U. K., Jander, S., Pepinsky, R. B., Lobb, R. R., Stoll, G., Toyka, K. V., & Gold, R. (2002) · Acta Neuropathologica · doi:10.1007/s004010100444 · Cited by 54
Medical Therapy for Crohn's Disease
Stein, R. B., & Lichtenstein, G. R. (2001) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70274-7 · Cited by 45
Cited by
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationAbraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
The immunological and genetic basis of inflammatory bowel disease
Bouma, G., & Strober, W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1132 · Cited by 1,767
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
Metadata
- Authors
- Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-02
- Volume
- 348
- Issue
- 1
- Pages
- 24-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138223843
- Cited by
- 808
- References
- 23
- FWCI
- 43.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.